Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescence [0.03%]
一种新型内在荧光特性表皮生长因子受体酪氨酸激酶抑制剂
Amelia Kierasińska-Kałka,Adrianna Rutkowska,Jacek Mularski et al.
Amelia Kierasińska-Kałka et al.
Kinase inhibitors are commonly used in research and clinical practice. Among them, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as afatinib and osimertinib, constitute an important subclass. T...
The novel agent VP79s synergistically enhances venetoclax activity in multiple myeloma cells [0.03%]
新型制剂VP79s能协同增强苯达莫司汀在多发性骨髓瘤细胞中的活性
Yunlong Pei,Jiaxun Wang,Taylor Smith et al.
Yunlong Pei et al.
Despite advances in new therapies, multiple myeloma (MM) remains incurable with most patients relapsing or becoming refractory to treatment demonstrating the need for novel therapeutic strategies. We previously identified VP79s, a novel gua...
Characterizing the post-market safety profile of lazertinib: a pharmacovigilance study of the FDA Adverse Events Reporting System Database [0.03%]
来特昔替尼上市后安全性特征的药物流行病学研究
Connor Frey
Connor Frey
Lazertinib is a third-generation, brain-penetrant, mutant-selective EGFR tyrosine kinase inhibitor approved for first-line treatment of EGFR-mutated non-small cell lung cancer, including in combination with amivantamab. Post-market safety s...
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors [0.03%]
LP-184（一种新型烷化剂类药物）治疗晚期实体瘤的首次人体I期临床研究
Daruka Mahadevan,Jay Parekh,Joseph T Beck et al.
Daruka Mahadevan et al.
LP-184 is a novel acylfulvene pro-drug that alkylates DNA after bioactivation by the intracellular oxidoreductase prostaglandin reductase 1 (PTGR1). In preclinical studies, potent growth inhibition has been observed against a wide variety o...
Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study [0.03%]
PEGATHORⅡ期研究：佩佐利尤单抗(SAR444245/THOR-707)联合派姆单抗或西妥昔单抗治疗晚期转移性胃肠道肿瘤的疗效评估
William P Harris,Pilar García-Alfonso,Jean Phillipe Metges et al.
William P Harris et al.
Pegenzileukin (SAR444245) is a pegylated recombinant human IL-2 variant designed to expand effector T cells and NK cells without stimulating regulatory T cells. This study evaluated pegenzileukin with pembrolizumab or cetuximab for treating...
Characterizing the post-market safety profile of cemiplimab: a pharmacovigilance study of the FDA adverse events reporting system database [0.03%]
赛米利单抗上市后安全性的药物流行病学研究：FDA不良事件报告系统数据库分析
Connor Frey
Connor Frey
Cemiplimab is a fully human PD-1 inhibitor approved for cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. Post-market safety surveillance is essential given the broad and evolving indications for immun...
Clinical features, diagnosis and prognosis of nivolumab-associated fulminant type 1 diabetes [0.03%]
nivolumab相关重症1型糖尿病的临床特征、诊断及预后
Qiong Liu,Qi Huang,Wei Sun et al.
Qiong Liu et al.
Fulminant type 1 diabetes (FT1D) is a rare immune-related adverse event associated with nivolumab, and its clinical characteristics remain unclear. This study aims to characterize the clinical features of nivolumab-associated FT1D and to ge...
Allogeneic hematopoietic stem cell transplantation with liposomal mitoxantrone conditioning for extramedullary leukemia [0.03%]
自体造血干细胞移植联合瘤可宁方案治疗髓外白血病
Lei Deng,Xiaolin Yu,Xiaocheng Song et al.
Lei Deng et al.
Leukemia relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the leading death cause, with extramedullary disease history as an independent relapse risk factor in acute leukemia. We analyzed 10 patients with...
Correction to: Prostate cancer cells' growth is decreased by novel MYC inhibitors [0.03%]
前列腺癌细胞的生长通过新型MYC抑制剂减少（Letter to the Editor）
Bita Nickkholgh,Joseph McGrath,Sivanandane Sittadjody et al.
Bita Nickkholgh et al.
Published Erratum
Investigational new drugs. 2026 Jun 13. DOI:10.1007/s10637-026-01620-4 2026
Effector-to-target ratio as a translational bottleneck for CD33 T-cell engagers in acute myeloid leukemia: a quantitative reanalysis of AMG 330 [0.03%]
靶向急性髓系白血病CD33的T细胞衔接蛋白的转化瓶颈：AMG 330的定量再分析结果中效应物与目标的比例失调
Hamid Bellout
Hamid Bellout
A common, often unstated paradigm in T-cell engager (TCE) translation assumes that target-antigen density and drug exposure are the main efficacy drivers, with effector context secondary. This paradigm is visible in dose-escalation strategi...